Results 21 to 30 of about 693,546 (355)

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Neurological Therapeutics, 2023
Introduction Foslevodopa/foscarbidopa, a soluble formulation of levodopa/carbidopa (LD/CD) prodrugs for the treatment of Parkinson’s disease (PD), is administered as a 24-hour/day continuous subcutaneous infusion (CSCI) with a single infusion site.
J. Aldred, Eric Freire-Álvarez, A. Amelin, A. Antonini, B. Bergmans, F. Bergquist, Manon Bouchard, K. Budur, C. Carroll, K. Chaudhuri, S. Criswell, E. Danielsen, F. Gandor, Jia Jia, T. Kimber, H. Mochizuki, W. Robieson, A. Spiegel, D. Standaert, S. Talapala, M. Facheris, V. Fung   +21 more
semanticscholar   +1 more source

Randomized controlled trial of a home-based action observation intervention to improve walking in Parkinson disease [PDF]

, 2016
Published in final edited form as: Arch Phys Med Rehabil. 2016 May ; 97(5): 665–673. doi:10.1016/j.apmr.2015.12.029.OBJECTIVE: To examine the feasibility and efficacy of a home-based gait observation intervention for improving walking in Parkinson ...
Cronin-Golomb, Alice, Ellis, Terry D., Jaywant, Abhishek, Lin, Cheng-Chieh, Neargarder, Sandy, Roy, Serge   +5 more
core   +1 more source

Pros and cons for statins use and risk of Parkinson's disease: An updated perspective

Pharmacology Research & Perspectives, 2023
Parkinson's disease (PD) is the second most frequent neurodegenerative brain disease (NBD) after Alzheimer's disease (AD). Statins are the most common lipid‐lowering agents used in the management of dyslipidemia and the prevention of primary and ...
H. Al-kuraishy, A. Al-Gareeb, A. Alexiou, M. Papadakis, A. Alsayegh, N. Almohmadi, H. Saad, G. Batiha   +7 more
semanticscholar   +1 more source

The mPower Study, Parkinson Disease Mobile Data Collected Using Researchkit [PDF]

, 2016
Current measures of health and disease are often insensitive, episodic, and subjective. Further, these measures generally are not designed to provide meaningful feedback to individuals.
Abhishek Pratap, Andrew D. Trister, Arno Klein, Brian M. Bot, Christine Suver, Christopher Bare, E. Ray Dorsey, Elias Chaibub Neto, John Wilbanks, Megan Doerr, Michael Kellen, Stephen H. Friend   +11 more
core   +1 more source

Levodopa Responsiveness in Adult‐onset Lower Limb Dystonia is Associated with the Development of Parkinson's Disease

Tremor and Other Hyperkinetic Movements, 2013
Background: Adult‐onset primary lower limb dystonia (AOPLLD) has been reported as an early sign of Parkinson’s disease (PD) or Parkinson‐plus syndrome in case series.
Florence C. F. Chang, Keith A. Josephs
doaj   +1 more source

Trial of Prasinezumab in Early-Stage Parkinson's Disease.

New England Journal of Medicine, 2022
BACKGROUND Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson's disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson's disease.
G. Pagano, Kirsten I. Taylor, J. Anzures‐Cabrera, M. Marchesi, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, J. Azulay, B. Mollenhauer, L. Lopez-Manzanares, D. Russell, J. Boyd, A. Nicholas, M. Luquin, R. Hauser, T. Gasser, W. Poewe, Benedicte Ricci, Anne Boulay, A. Vogt, F. Boess, J. Dukart, Giulia D’Urso, R. Finch, S. Zanigni, Annabelle Monnet, N. Pross, Andrea Hahn, H. Svoboda, Markus Britschgi, F. Lipsmeier, E. Volkova-Volkmar, M. Lindemann, S. Dziadek, Š. Holiga, Daria Rukina, T. Kustermann, G. Kerchner, P. Fontoura, D. Umbricht, R. Doody, T. Nikolcheva, A. Bonni   +44 more
semanticscholar   +1 more source

Superoxide Dismutase (SOD)-mimetic M40403 is protective in cell and fly models of paraquat toxicity: Implications for Parkinson disease [PDF]

, 2016
Parkinson disease is a debilitating and incurable neurodegenerative disorder affecting 3c1-2% of people over 65 years of age. Oxidative damage is considered to play a central role in the progression of Parkinson disease and strong evidence links chronic
Beltramini, Mariano, Bisaglia, Marco, Bubacco, Luigi, Casella, Luigi, Ferrari, Emanuele, Filograna, Roberta, Godena, Vinay K., Sanchez Martinez, Alvaro, Whitworth, Alexander J.   +8 more
core   +1 more source

Trial of Cinpanemab in Early Parkinson's Disease.

New England Journal of Medicine, 2022
BACKGROUND Aggregated α-synuclein plays an important role in Parkinson's disease pathogenesis. Cinpanemab, a human-derived monoclonal antibody that binds to α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease ...
A. Lang, A. Siderowf, E. Macklin, W. Poewe, D. Brooks, Hubert H. Fernandez, O. Rascol, Nir Giladi, F. Stocchi, C. Tanner, R. Postuma, D. Simon, E. Tolosa, B. Mollenhauer, J. Cedarbaum, Kyle Fraser, James Xiao, K. Evans, Danielle L. Graham, Inbal Sapir, Jennifer A. Inra, R. Hutchison, Minhua Yang, Tara Fox, Samantha Budd Haeberlein, T. Dam   +25 more
semanticscholar   +1 more source

Structural MRI Correlates of Episodic Memory Processes in Parkinson's Disease Without Mild Cognitive Impairment. [PDF]

, 2015
BackgroundChanges in episodic memory are common early in Parkinson's disease (PD) and may be a risk factor for future cognitive decline. Although medial temporal lobe (MTL) memory and frontostriatal (FS) executive systems are thought to play different ...
Filoteo, J Vincent, Harrington, Deborah L, Litvan, Irene, Pirogovsky-Turk, Eva   +3 more
core   +2 more sources

A Pilot Study of the Feasibility and Effects of Table Tennis Training in Parkinson Disease

Archives of Rehabilitation Research and Clinical Translation, 2020
Objective: To investigate feasibility and effects of table tennis training on balance control and physical function in individuals with Parkinson disease. Design: Single group, observational, before-after trial.
Karin Olsson, MD, Erika Franzén, PT, PhD, Anders Johansson, MD, PhD   +2 more
doaj   +1 more source